Building a Genomics-Driven Cancer Prevention Ecosystem in Latin America

A shift to proactive cancer prevention in Latin America leverages genomic medicine by integrating risk testing into primary care, enhancing education, and utilizing cascade screening to improve outcomes.

Life Sciences Review | Tuesday, February 17, 2026

A global shift in oncology is redefining the field, moving from treatment-centered care to proactive prevention driven by the integration of genomic medicine into everyday healthcare. For Latin America, this represents a monumental opportunity to leapfrog traditional healthcare models and build a future where hereditary cancer risk is identified and managed long before it manifests as disease. By strategically embedding cancer risk testing into the foundational pillars of primary care and public health, the region can create a scalable, high-impact prevention system. The success of this vision rests on three interconnected cornerstones: innovative implementation models, the powerful multiplier effect of cascade screening, and a deep commitment to clinician education.

The New Frontier of Proactive Health

The ability to screen for hereditary cancer risk involves analyzing an individual's DNA to identify specific inherited genetic mutations, known as pathogenic variants, that significantly increase their lifetime risk for developing certain cancers. While the most widely recognized genes are associated with breast, ovarian, prostate, and pancreatic cancers, the scope of testing has expanded to include a panel of other critical genes. These include those linked to Lynch syndrome, which elevate the risk for colorectal, endometrial, and other cancers.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

The core principle is to move this powerful tool from the exclusive domain of specialized oncology centers directly into the community. Identifying at-risk individuals is not merely an academic exercise; it is the first step in a life-saving clinical pathway. An individual found to carry a pathogenic variant can be enrolled in personalized management programs that include enhanced surveillance protocols (such as more frequent mammograms or colonoscopies), risk-reducing medications, and preventive surgeries. This proactive stance transforms the healthcare journey from reactive to anticipatory, empowering individuals and their physicians with the foresight to act decisively.

Innovative Implementation Models for Broad Access

The Integrated Primary Care Model positions primary care physicians (PCPs) as the central agents in identifying individuals at risk. By equipping PCPs with simple, validated tools—such as family history questionnaires—genetic risk assessment can be seamlessly integrated into routine care. Eligible patients provide a saliva or blood sample, and results are returned with clear, actionable guidance. Positive findings prompt referrals to genetic counselors or specialists, ensuring continuity of care and democratizing access through the most common healthcare touchpoint.

The Public Health Program Model expands reach through population-level initiatives led by national or regional health ministries, integrating genetic testing into existing programs like women’s health campaigns or cancer awareness drives. This ensures equitable access by offering testing to defined groups—such as all ovarian cancer patients or women over a certain age—and positions genetic testing as a core preventive health service. Complementing these, the Digital Health and Telegenetics Model uses secure online platforms for risk assessment, education, and post-test counseling, enabling remote participation and specialist access regardless of geography.

Empowering Families and Clinicians Through Cascade Screening

The most powerful strategy for maximizing the impact of genetic testing is cascade screening. For every individual identified through a clinical or public health program, cascade screening can identify several more at-risk family members. This approach is exceptionally efficient and cost-effective because it focuses testing on those with the highest probability of being carriers. It transforms a single test result into a wave of preventive action that can ripple through an entire family, potentially averting multiple future cancer diagnoses across generations. This family-centered approach to health resonates deeply with the strong familial and community bonds prevalent in Latin American culture, making it a socially and clinically compelling strategy.

The most sophisticated testing technologies and implementation models are only as effective as the healthcare professionals who wield them. Therefore, a robust and continuous commitment to clinician education is the indispensable final pillar for successful integration. The goal is to build confidence and competence among a wide range of healthcare providers, particularly those in primary care.

Educational initiatives must be practical, accessible, and ongoing. Key training modules should cover the fundamentals of cancer genetics, clear guidelines on who is eligible for testing, and best practices for interpreting and communicating results. Crucially, this education must also focus on the clinical management pathways following a positive outcome, ensuring that providers know precisely which steps to take to connect patients with appropriate surveillance and risk-reduction options. Delivery of this education can take many forms, from accredited online courses and interactive workshops to partnerships with national medical societies. Furthermore, integrating clinical decision-support tools directly into electronic health records can provide real-time guidance, helping physicians identify at-risk patients and navigate management protocols effortlessly. By empowering the front lines, the healthcare system ensures that every genetic test is a gateway to meaningful clinical action.

By weaving together these threads—innovative delivery models, the exponential power of cascade screening, and a foundational investment in education—Latin America is poised to build a world-class health ecosystem defined by prevention. The journey is one of empowerment, foresight, and a shared vision for a future where hereditary cancer is not a destiny. Still, a manageable condition was intercepted at its earliest, most preventable stage.

More in News

Growing Concerns About Data Continuity in Biopharma Evidence Generation

One of the common concerns within biopharma is not a matter of generating evidence per se. What makes it even harder is the possibility of sustaining a consistent stream of information through several studies or regulations over prolonged periods of time. As such, the issue of data continuity gains more importance as evidence generation software solutions are currently evaluated by potential buyers. Evidentiary initiatives are never limited to the sole scope of their objectives. Information retrieved once can become relevant several times over the life cycle of a particular product. Researchers may need to re-examine certain findings, compare results of treatment between different periods of time or study data acquired within separate research processes. It becomes especially complicated if there are no consistent information sources within an organization. Such considerations begin to impact the choice of evidence generation software. While the tools themselves are hardly ever used to produce any scientific insights directly, their contribution lies in facilitating further evidence processing and management. The problem becomes apparent as evidentiary research programs move past their initial objectives. It is rare for evidence generation initiatives to have a definite deadline or goal. Several years may pass between the start of the research process and its end, which means that there can be many staff changes, reconsiderations of previous assumptions or emergence of new questions. When information proves hard to find or analyze, the whole process can be slowed down significantly. The amount of effort spent tracking documents, verifying the integrity of information and understanding research history may prove to be considerable. At the same time, these aspects might not become a major focus of technology evaluation. Procurement conversations about evidence generation software solutions are shifting in this direction. Buyers' attention moves from operational effectiveness to information sustainability as evidence programs grow more extensive and complex. They are starting to see evidence generation software platforms as tools for sustaining knowledge over time rather than project management resources. This brings a change to the list of priorities for software developers. Features aimed at optimizing research processes are essential but buyers become concerned with data preservation as well. As such, information continuity becomes part of a solution's institutional memory function rather than just another aspect of project management. While data continuity may not be as prominent as some new trends in evidence analytics, it addresses a pressing problem faced by many biopharma teams. Evidence generation projects tend to outlast their budgets, original objectives or even the members of a team conducting research. For biopharma companies investing in such tools, the problem is shifting from acquiring new information to keeping existing data context-sensitive. ...Read more

Choosing Microbial CDMO without Losing Process Control

Commercial biologics programs rarely stall because a sponsor failed to reserve manufacturing capacity. Delays are more likely to appear when fermentation assumptions, purification readiness, assay design and batch documentation fall out of sync. Microbial manufacturing is particularly sensitive at this stage. A process that performs well during development can quickly lose momentum if harvest conditions are not fully understood or impurity clearance has not been aligned with the characteristics of the molecule. For executives evaluating a CDMO, manufacturing capacity is important, but maintaining process continuity is even more critical. The strongest CDMOs do not treat development and manufacturing as separate stages handed from one department to another. Instead, they manage them as a continuous, controlled process. Analytical strategy is developed while the process is still being refined, manufacturing constraints are identified before GMP transfer, sampling routes are planned early and documentation evolves alongside the program instead of being rebuilt for clinical or commercial manufacturing. This goes beyond administrative efficiency. It is an important part of controlling risk. Changes to analytical methods or batch records late in development can trigger comparability work and make regulatory review more challenging. "Richter BioLogics aligns well with the priorities many sponsors look for when they need microbial expertise backed by GMP manufacturing." A thorough evaluation should also examine how fermentation and purification work together in practice. Separate upstream and downstream suites can offer sponsors greater flexibility, but only if the transition between them is carefully managed. Having real-time harvest data, purification teams ready to receive material, buffers prepared in advance and clear sample routes in place helps avoid the disruption that often occurs between the bioreactor and the first chromatography step. The same level of scrutiny applies to plasmid DNA manufacturing, where supercoiled content, host-cell impurities, endotoxin burden and unwanted isoforms all influence whether the final material is suitable for its intended use. Quality systems should be assessed through evidence, not broad assurances. Every GMP manufacturing program generates extensive documentation, and that record should remain clear and consistent from raw material receipt and media preparation through in-process testing, deviations, investigations and final product release. Buyers should look at whether quality control is integrated closely enough with manufacturing to detect early process signals. They should also consider whether the CDMO has the in-house analytical expertise needed for release testing, stability studies, troubleshooting and comparability work, instead of relying on outside laboratories whenever challenges arise. "For sponsors working to demanding timelines, Richter BioLogics brings together specialized microbial expertise, disciplined documentation, in-house analytical testing and direct project coordination." Scale also deserves careful consideration. A larger facility does not automatically make decisions faster, and a smaller specialist may not have enough built-in redundancy. A better question is whether the manufacturing model gives sponsors direct access to scientific expertise while providing the GMP infrastructure needed to support late-stage development and commercial production. That balance is especially important in microbial biologics. Therapeutic proteins, antibody fragments, bacterial vaccines and plasmid DNA each bring different manufacturing demands, so buyers should look beyond broad claims about capacity and examine the depth of process and analytical expertise behind them. Richter BioLogics aligns well with the priorities many sponsors look for when they need microbial expertise backed by GMP manufacturing. Its capabilities span process development, analytical development, microbial GMP manufacturing and plasmid DNA production, including the pART plasmid platform. The company operates independent upstream and downstream processing lines across two multiproduct GMP facilities, with quality control integrated throughout manufacturing campaigns. It supports therapeutic proteins, VHH or Nanobody formats, bacterial vaccines and plasmid DNA. A long GMP manufacturing track record, recent capacity expansion, in-house analytical capabilities and a 2026 FDA inspection with zero observations provide added confidence. For sponsors working to demanding timelines, Richter BioLogics brings together specialized microbial expertise, disciplined documentation, in-house analytical testing and direct project coordination. ...Read more

Inventus welcomes senior figure from Google as a board adviser

Inventus, the only company in the world dedicated to creating purpose-built devices and technology solutions exclusively for clinical trials, has made a key appointment from Google to its advisory board. Mark Bennett, a Vice President at Google, will be working with Inventus in the capacity of Board Adviser. Bennett has more than two decades in senior leadership roles at companies including Microsoft, Sainsbury’s & Tesco. He is currently Google’s Vice President of Knowledge & Information Partnerships for the EMEA region, leading product partnerships for Search, Gemini, Maps, Commerce, Research and Ads . Bennett has spent more than 10 years in Google Partnerships across a range of teams including Knowledge & Information, Android, Google Hardware and Google Play. Bennett’s previous roles at Google include VP for Platforms and Devices Partnerships for the APAC region and Vice President for Google’s Global Android Partnerships. Bennett said he was excited to support Inventus - known for its innovative and industry leading clinical trial solutions - to help map out its next phase of growth. He said: “I’m delighted to be advising the board at Inventus. I’m impressed by the growth and strategy of the company and am looking forward to helping them accelerate that trajectory. I’ve been intrigued by the biomedical sciences sector for some time and seen how AI is an increasingly important factor for the industry. I’ll be advising Inventus on how technology can be harnessed to enhance the efficiency, effectiveness and overall impact of clinical trials, helping bring better treatments to patients faster.” Bennett is the second key appointment from Google at Inventus in recent months. Earlier this year, Jon French, Managing Director of Google’s Android Global Business, was appointed Group Managing Director at Inventus. Commenting on Bennett’s new role, French said: “I could not be more excited to welcome Mark to the Inventus advisory board. I know personally what an incredible leader Mark is. His expertise and perspective will be tremendous assets to our business. “As Inventus enters its next phase of growth, his experience, judgement and strategic vision will help shape our direction and strengthen our ability to achieve our long-term ambitions. At the heart of everything we do at Inventus is a commitment to help bring life-changing treatments to patients faster.” Bennett is the second appointment to the Inventus advisory board – he joins Stacy Hurt, chief patient officer at Parexel, who was welcomed as a Board Adviser in the summer. Parexel is a global clinical development partner. Hurt leads efforts to integrate patient perspectives into drug development and healthcare at their earliest stages. Hurt has more than two decades of leadership experience in the pharmaceutical space. She has worked for GlaxoSmithKline, Transdermal Therapeutics and Colon Cancer Coalition across sales, training and development and has over a decade of experience in patient advocacy. Steve Sanghera, CEO and Co-Founder of Inventus, said: “I am delighted to announce the exceptional appointment of Mark Bennett to the Inventus Board. Mark brings world class technology leadership and knowledge which will be instrumental in guiding our journey as we navigate how AI will shape and influence clinical trials. Mark’s appointment reflects the continuous growth of Inventus within the industry. Together with Stacy, the expertise that we now have at Inventus also demonstrates our commitment to building a business that focuses on technological excellence and the patients which sit at the heart of a clinical trial.” ...Read more

Inventus welcomes senior figure from Google as a board adviser

Specials

Building a Genomics-Driven Cancer Prevention Ecosystem in Latin America

A shift to proactive cancer prevention in Latin America leverages genomic medicine by integrating risk testing into primary care, enhancing education, and utilizing cascade screening to improve outcomes.